Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories (ABT) is a global healthcare leader driving innovations in medical devices, diagnostics, nutrition, and branded generics. This page provides investors and industry professionals with timely updates on the company’s latest developments, strategic initiatives, and regulatory milestones.
Access Abbott’s official press releases alongside curated analysis of key events impacting its diversified business segments. Track updates across diabetes care technologies, cardiovascular device approvals, diagnostic system launches, and nutritional product expansions. Our repository ensures you stay informed about earnings announcements, partnership agreements, and clinical trial outcomes without speculative commentary.
Bookmark this page for streamlined access to Abbott’s evolving market position and evidence-based insights into its global healthcare solutions. Check regularly for verified updates that matter to your investment research or industry analysis.
Rhea-AI Summary
Abbott (NYSE: ABT) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
-
Rhea-AI Summary
Abbott (NYSE: ABT) increases its quarterly common dividend by 7.8% to 55 cents per share, marking 52 years of consecutive dividend growth. The company will pay its 400th consecutive quarterly dividend since 1924 on Feb. 15, 2024. Abbott is a member of the S&P 500 Dividend Aristocrats Index, demonstrating its commitment to delivering strong shareholder returns and top-tier growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
-
Rhea-AI Summary
Surmodics, Inc. (NASDAQ:SRDX) announced the 36-month data from its TRANSCEND clinical trial, presenting the safety and efficacy of the SurVeil drug coated balloon (DCB) compared to the IN.PACT Admiral DCB for treating superficial femoral and proximal popliteal artery lesions. The primary efficacy and safety endpoints showed comparable outcomes, demonstrating the non-inferiority of the SurVeil DCB to the IN.PACT Admiral DCB. Dr. Peter A. Schneider presented the data at the 50th Annual VEITH Symposium in New York, New York.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
Rhea-AI Summary
Abbott (NYSE: ABT) has announced new data from the ARIES trial, showing that advanced heart failure patients living with its HeartMate 3™ heart pump who didn't receive aspirin as part of their blood-thinning medication regimen experienced fewer complications from bleeding and were associated with reduced hospital visits compared to patients who took aspirin daily following their implant. The data from the ARIES trial is the first to potentially shift how physicians manage their patients living with a HeartMate 3 heart pump. The trial studied more than 600 patients and found that HeartMate 3 patients who didn't receive aspirin but continued using the standard post-implant vitamin-K antagonist (VKA) treatment regimen met the primary endpoint by showing non-inferiority of no aspirin to aspirin. The ARIES trial also revealed cost-savings for heart failure patients who did not take aspirin following implant of an Abbott HeartMate 3 pump, with a 41% reduction in estimated costs related to bleeding events one year after receiving the device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
-
Rhea-AI Summary
Abbott (NYSE: ABT) study shows Healthy Food Rx program's positive impact on diabetes management and diet quality in Stockton, Calif.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
-
News
Rhea-AI Summary
Surmodics, Inc. (NASDAQ:SRDX) announced that 36-month data from its TRANSCEND clinical trial will be presented at the 50th Annual VEITH Symposium. Dr. Peter A. Schneider will share the trial's safety and efficacy data in a session focused on randomized controlled trial updates on drug coated balloons and drug eluting stents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
Rhea-AI Summary
Abbott announced 'Countdown at a Crossroads,' a campaign to raise awareness of diabetes and promote access to continuous glucose monitoring (CGM) systems. The campaign includes an animated installation at the Oculus Center in New York City featuring people impacted by diabetes. Every visit to www.Crossroads.Abbott in November triggers a donation to the American Diabetes Association's Health Equity Now program. Abbott aims to make CGM technology more accessible and affordable, as only 1% of adults with diabetes currently use it.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
-
Rhea-AI Summary
Abbott has received FDA approval for its molecular HPV screening solution, expanding its Alinity m family of diagnostic assays. The test detects high-risk HPV infections that could lead to cancer and provides genotype determination on the 14 cancer-causing types of HPV. It is approved for use as a primary screen for cervical cancer and can be used in combination with a Pap test. The Alinity m HR HPV assay delivers information on five risk groups covering the 14 potentially cancer-causing genotypes, enabling physicians to assess the risk and tailor follow-up for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
-
Rhea-AI Summary
Abbott (NYSE:ABT) has announced the launch of the Abbott HeartMates program, a new initiative aimed at creating a supportive community for people impacted by heart conditions. The program will provide emotional support, storytelling, and connection opportunities for participants. Professional football player Damar Hamlin will serve as the program's first ambassador. Heart disease affects over 100 million Americans, and the program aims to empower individuals to achieve their own comeback stories.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
Rhea-AI Summary
Abbott announced 'Countdown at a Crossroads,' an animated installation at the Oculus Center in New York City to raise awareness of diabetes and the benefits of continuous glucose monitoring (CGM) systems. The installation features the faces and stories of people impacted by diabetes, including Sherri Shepherd. Every visit to www.Crossroads.Abbott during National Diabetes Awareness Month triggers a donation to the American Diabetes Association's Health Equity Now program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
Abbott Labs
NYSE:ABT
ABT Rankings
ABT Stock Data
227.16B
1.72B
0.54%
79.44%
1.32%
Medical Devices
Pharmaceutical Preparations
United States
ABBOTT PARK